These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report. Ashraf S; Alsharedi M Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma. Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660 [TBL] [Abstract][Full Text] [Related]
6. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel. Lebas E; Marchal N; Rorive A; Nikkels AF Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680 [TBL] [Abstract][Full Text] [Related]
7. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios. Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984 [TBL] [Abstract][Full Text] [Related]
8. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab]. Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461 [TBL] [Abstract][Full Text] [Related]
9. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948 [TBL] [Abstract][Full Text] [Related]
10. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. Hughes BGM; Guminski A; Bowyer S; Migden MR; Schmults CD; Khushalani NI; Chang ALS; Grob JJ; Lewis KD; Ansstas G; Day F; Ladwa R; Stein BN; Muñoz Couselo E; Meier F; Hauschild A; Schadendorf D; Basset-Seguin N; Modi B; Dalac-Rat S; Dunn LA; Flatz L; Mortier L; Guégan S; Heinzerling LM; Mehnert JM; Trabelsi S; Soria-Rivas A; Stratigos AJ; Ulrich C; Wong DJ; Beylot-Barry M; Bossi P; Bugés Sánchez C; Chandra S; Robert C; Russell JS; Silk AW; Booth J; Yoo SY; Seebach F; Lowy I; Fury MG; Rischin D J Am Acad Dermatol; 2025 Jan; 92(1):68-77. PubMed ID: 39245360 [TBL] [Abstract][Full Text] [Related]
11. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma. Lai FY; Clarke R; Cooper P; Stokes J; Calvert P Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839 [TBL] [Abstract][Full Text] [Related]
12. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients. Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma. Boutros A; Cecchi F; Tanda ET; Croce E; Gili R; Arecco L; Spagnolo F; Queirolo P Front Oncol; 2021; 11():733917. PubMed ID: 34513710 [TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma. Giri A; Bauman JR Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496 [TBL] [Abstract][Full Text] [Related]